Literature DB >> 31080694

Human Pentraxins Bind to Misfolded Proteins and Inhibit Production of Type I Interferon Induced by Nucleic Acid-Containing Amyloid.

Stephanie M Dorta-Estremera1,2, Wei Cao1,2.   

Abstract

OBJECTIVE: Amyloid deposition is linked to multiple human ailments, including neurodegenerative diseases, type 2 diabetes, and systemic amyloidosis. The assembly of misfolded proteins into amyloid fibrils involves an intermediate form, i.e., soluble amyloid precursor (AP), which exerts cytotoxic function. Insoluble amyloid also stimulates innate immune cells to elicit cytokine response and inflammation. How any of these misfolded proteins are controlled by the host remains obscure. Serum amyloid-P component (SAP) is a universal constituent of amyloid deposits. Short-chain pentraxins, which include both SAP and C-reactive protein (CRP), are pattern recognition molecules that bind to diverse ligands and promote the clearance of microbes and cell debris. Whether these pentraxins interact with AP and cofactor-containing amyloid and subsequently impact their function is not known. METHODS AND
RESULTS: To detect the interaction between SAP and different types of amyloids, we performed dot blot analysis. The results showed that SAP invariably bound to protein-only, nucleic acid-containing and glycosaminoglycan-containing amyloid fibrils. This interaction required the presence of calcium. By ELISA, both SAP and CRP bound to soluble AP in the absence of divalent cations. Further characterization, by gel filtration, implied that SAP decamer may recognize AP whereas aggregated SAP preferentially associates with amyloid fibril. Although SAP binding did not affect cytotoxic function of AP, SAP potently inhibited the production of interferon-α from human plasmacytoid dendritic cells triggered by DNA-containing amyloid.
CONCLUSIONS: Our data suggest that short pentraxins differentially interact with various forms of misfolded proteins and, in particular, modulate the ability of nucleic acid-containing amyloid to stimulate aberrant type I interferon response. Hence, pentraxins may function as key players in modulating the pathogenesis of protein misfolding diseases as well as interferon-mediated autoimmune manifestation.

Entities:  

Keywords:  Amyloid; C-reactive protein; Interferon; Pentraxins; Plasmacytoid dendritic cells; Protein misfolding; Serum amyloid P component

Year:  2015        PMID: 31080694      PMCID: PMC6510259          DOI: 10.4172/2155-9899.1000332

Source DB:  PubMed          Journal:  J Clin Cell Immunol


  64 in total

1.  Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo.

Authors:  Dominic M Walsh; Igor Klyubin; Julia V Fadeeva; William K Cullen; Roger Anwyl; Michael S Wolfe; Michael J Rowan; Dennis J Selkoe
Journal:  Nature       Date:  2002-04-04       Impact factor: 49.962

2.  Getting out of shape.

Authors:  Christopher M Dobson
Journal:  Nature       Date:  2002-08-15       Impact factor: 49.962

3.  Extracellular calcium elicits a chemokinetic response from monocytes in vitro and in vivo.

Authors:  I T Olszak; M C Poznansky; R H Evans; D Olson; C Kos; M R Pollak; E M Brown; D T Scadden
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

4.  Human serum amyloid P component is a single uncomplexed pentamer in whole serum.

Authors:  W L Hutchinson; E Hohenester; M B Pepys
Journal:  Mol Med       Date:  2000-06       Impact factor: 6.354

5.  Molecular chaperone properties of serum amyloid P component.

Authors:  A R Coker; A Purvis; D Baker; M B Pepys; S P Wood
Journal:  FEBS Lett       Date:  2000-05-12       Impact factor: 4.124

6.  Binding of serum amyloid P-component (SAP) by amyloid fibrils.

Authors:  M B Pepys; R F Dyck; F C de Beer; M Skinner; A S Cohen
Journal:  Clin Exp Immunol       Date:  1979-11       Impact factor: 4.330

7.  Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis.

Authors:  M B Pepys; J Herbert; W L Hutchinson; G A Tennent; H J Lachmann; J R Gallimore; L B Lovat; T Bartfai; A Alanine; C Hertel; T Hoffmann; R Jakob-Roetne; R D Norcross; J A Kemp; K Yamamura; M Suzuki; G W Taylor; S Murray; D Thompson; A Purvis; S Kolstoe; S P Wood; P N Hawkins
Journal:  Nature       Date:  2002-05-16       Impact factor: 49.962

8.  A glimpse of a possible amyloidogenic intermediate of transthyretin.

Authors:  K Liu; H S Cho; H A Lashuel; J W Kelly; D E Wemmer
Journal:  Nat Struct Biol       Date:  2000-09

9.  Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases.

Authors:  Monica Bucciantini; Elisa Giannoni; Fabrizio Chiti; Fabiana Baroni; Lucia Formigli; Jesús Zurdo; Niccolò Taddei; Giampietro Ramponi; Christopher M Dobson; Massimo Stefani
Journal:  Nature       Date:  2002-04-04       Impact factor: 49.962

10.  Structural properties of an amyloid precursor of beta(2)-microglobulin.

Authors:  Victoria J McParland; Arnout P Kalverda; Steve W Homans; Sheena E Radford
Journal:  Nat Struct Biol       Date:  2002-05
View more
  1 in total

1.  Structurally Altered, Not Wild-Type, Pentameric C-Reactive Protein Inhibits Formation of Amyloid-β Fibrils.

Authors:  Donald N Ngwa; Alok Agrawal
Journal:  J Immunol       Date:  2022-08-17       Impact factor: 5.426

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.